About VERAXA
VERAXA is a company based in Heidelberg (Germany) founded in 2017 by Edward A. Lemke, Christoph A. Merten, and Christine Köhler.. VERAXA has raised $3.41 million across 1 funding round. VERAXA has completed 1 acquisition, including SYNIMMUNE. VERAXA offers products and services including BiTAC Technology, ADC Technology, and Functional Antibody Screening. VERAXA operates in a competitive market with competitors including Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
- Headquarter Heidelberg, Germany
- Founders Edward A. Lemke, Christoph A. Merten, Christine Köhler
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Veraxa Biotech Gmbh
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$3.41 M (USD)
in 1 rounds
-
Latest Funding Round
$3.41 M (USD), Series B
Jun 27, 2019
-
Investors
-
Employee Count
Employee Count
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of VERAXA
VERAXA offers a comprehensive portfolio of products and services, including BiTAC Technology, ADC Technology, and Functional Antibody Screening. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for bispecific T-cell engagers in oncology treatments.
Technology for antibody-drug conjugates targeting cancer with reduced side effects.
Method for screening antibodies to enhance therapeutic development.
Unlock access to complete
Unlock access to complete
Funding Insights of VERAXA
VERAXA has successfully raised a total of $3.41M through 1 strategic funding round. The most recent funding activity was a Series B round of $3.41 million completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series B — $3.4M
-
First Round
First Round
(27 Jun 2019)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2019 | Amount | Series B - VERAXA | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by VERAXA
VERAXA has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include SYNIMMUNE. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
German, early-stage biotech developing mono- and bi-specific antibodies for cancer treatment
|
2010 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - VERAXA
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Veraxa Comparisons
Competitors of VERAXA
VERAXA operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Digital sequencing technology for cancer detection is developed.
|
|
| domain | founded_year | HQ Location |
Genomics-based diagnostic tests for cancer are provided.
|
|
| domain | founded_year | HQ Location |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| domain | founded_year | HQ Location |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| domain | founded_year | HQ Location |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
|
| domain | founded_year | HQ Location |
Genetically engineered cell therapies are developed for multiple disorders.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Veraxa
Frequently Asked Questions about VERAXA
When was VERAXA founded?
VERAXA was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Where is VERAXA located?
VERAXA is headquartered in Heidelberg, Germany. It is registered at Heidelberg, Baden-wurttemberg, Germany.
Is VERAXA a funded company?
VERAXA is a funded company, having raised a total of $3.41M across 1 funding round to date. The company's 1st funding round was a Series B of $3.41M, raised on Jun 27, 2019.
What does VERAXA do?
VERAXA was founded in 2017 in Heidelberg, Germany, within the biotechnology sector. Antibody therapeutics for oncological conditions are developed through ADC engineering and functional antibody screening. Droplet-based microfluidic screening technology is utilized, along with innovative antibody and protein conjugation methods, to generate antibodies against complex target molecules. Operations focus on advancing treatments for cancer.
Who are the top competitors of VERAXA?
VERAXA's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
What products or services does VERAXA offer?
VERAXA offers BiTAC Technology, ADC Technology, and Functional Antibody Screening.
How many acquisitions has VERAXA made?
VERAXA has made 1 acquisition, including SYNIMMUNE.